On the 25th, UBI Pharma Inc. (6562.TW) announced that their new HIV combination drug, NDF-01, has been honored with the Best Product Category Award at the 20th National Brand Yushan Awards. Dr. Chi-Hsiang Chen, the Chairman and CEO, was also recognized with the Outstanding Corporate Leader Award.
NDF-01, UBI Pharma Inc.’s innovative HIV combination drug, is a three-component tablet that successfully completed academic clinical trials and published research papers in 2020. In 2022, it passed the rigorous bioequivalence tests in Taiwan, confirming its similarity to the reference drug. Following this achievement, after the completion of three production batches and stability testing, the company is poised to submit a drug certification application to the Taiwan Food and Drug Administration (TFDA).
Dr. Chi-Hsiang Chen brings a wealth of experience in the biotechnology industry, spanning biologics, pharmaceuticals, and business management. He assumed the role of General Manager at UBI Pharma Inc. on October 3, 2018, and took on the position of Chairman on December 1, 2019. Under his leadership, the company adeptly navigated the challenges brought about by the COVID-19 pandemic. He actively pursued improvements in the company’s infrastructure, explored opportunities in Contract Development and Manufacturing Organizations (CDMO), and attracted financial and strategic investors. This strategic focus led to the company’s financial turnaround in the 2020 fiscal year and a successful listing on the OTC market.
UBI Pharma Inc. achieved notable milestones, including facility inspections in Ukraine last year and, at the beginning of this year, a successful inspection by the Taiwan FDA. In August, the company received notice of its successful inspection by the U.S. FDA.
Dr. Chi-Hsiang Chen expressed his profound gratitude for receiving these prestigious awards. He underscored the company’s unwavering dedication to advancing research and development, upholding pharmaceutical quality, and strengthening corporate governance. Furthermore, he emphasized the company’s commitment to expediting the launch of new products. He envisions that the introduction of the biosimilar drug UB-851 and the new HIV combination drug NDF-01 will have a positive impact on a wider spectrum of patients, contributing to the company’s sustained revenue growth.
Original test：https://www.ctee.com.tw/news/
